Multiple sclerosis: Does nogo play a role?

Neuroscientist

Volumn 19, Issue 4, 2013, Pages 394-408

  Lee, Jae Young ^a   Petratos, Steven ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b RMIT UNIVERSITY   (Australia)

Author keywords

axonal degeneration; multiple sclerosis; Nogo; Nogo receptor; Nogo signaling; remyelination

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; MYELIN; NOGO A ANTIBODY; PROTEIN INHIBITOR; PROTEIN NOGO; PROTEIN NOGO A; PROTEIN NOGO B; PROTEIN NOGO C; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DEMYELINATION; DISEASE COURSE; ENCEPHALITIS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEOCORTEX; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REMYELINIZATION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY;

AXONAL DEGENERATION; MULTIPLE SCLEROSIS; NOGO; NOGO RECEPTOR; NOGO SIGNALING; REMYELINATION;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; MYELIN PROTEINS; NERVE DEGENERATION; NERVE FIBERS, MYELINATED; SIGNAL TRANSDUCTION;

EID: 84879919408     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858413477207     Document Type: Review

References (60)

1. Akbik F, Cafferty WB, Strittmatter SM. Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity. Exp Neurol. 2012 ; 235 (1). 43-52
2. Baer AS, Syed YA, Kang SU, Mitteregger D, Vig R, Ffrench-Constant C. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain. 2009 ; 132 (Pt 2). 465-81
3. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002 ; 416 (6881). 636-40
4. Cafferty WB, Strittmatter SM. The Nogo-Nogo receptor pathway limits a spectrum of adult CNS axonal growth. J Neurosci. 2006 ; 26 (47). 12242-50
5. Chang A, Staugaitis SM, Dutta R, Batt CE, Easley KE, Chomyk AM. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol. 2012 ; 72 (6). 918-26
6. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med. 2002 ; 346 (3). 165-73
7. Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ. The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J Neurosci. 2007 ; 27 (27). 7117-7124
8. Chong SY, Rosenberg SS, Fancy SP, Zhao C, Shen YA, Hahn AT. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad Sci U S A. 2012 ; 109 (4). 1299-304
9. Clemente D, Ortega MC, Arenzana FJ, de Castro F. FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J Neurosci. 2011 ; 31 (42). 14899-909
10. de Castro F, Bribian A. The molecular orchestra of the migration of oligodendrocyte precursors during development. Brain Res. 2005 ; 49 (2). 227-41
11. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci. 2002 ; 22 (15). 6570-7
12. Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat Neurosci. 2012 ; 15 (5). 703-12
13. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008 ; 9 (11). 839-55
14. Frantz S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotechnol. 2012 ; 30 (1). 12-3
15. Fry EJ, Ho C, David S. A role for Nogo receptor in macrophage clearance from injured peripheral nerve. Neuron. 2007 ; 53 (5). 649-62
16. Fujita Y, Takashima R, Endo S, Takai T, Yamashita T. The p75 receptor mediates axon growth inhibition through an association with PIR-B. Cell Death Dis. 2011 ; 2: e198
17. Haybaeck J, Llenos IC, Dulay RJ, Bettermann K, Miller CL, Walchli T. Expression of Nogo-A is decreased with increasing gestational age in the human fetal brain. Dev Neurosci. 2012 ; 34 (5). 402-16
18. Hunt D, Mason MR, Campbell G, Coffin R, Anderson PN. Nogo receptor mRNA expression in intact and regenerating CNS neurons. Mol Cell Neurosci. 2002 ; 20 (4). 537-52
19. Jtifon S, Vought B, Gross CH, Gan L, Austen D, Frantz JD. Lingo-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem. 2012 ; 287 (26). 22184-95
20. Josephson A, Widenfalk J, Widmer HW, Olson L, Spenger C. NOGO mRNA expression in adult and fetal human and rat nervous tissue and in weight drop injury. Exp Neurol. 2001 ; 169 (2). 319-28
21. Karimi-Abdolrezaee S, Schut D, Wang J, Fehlings MG. Chondroitinase and growth factors enhance activation and oligodendrocyte differentiation of endogenous neural precursor cells after spinal cord injury. PloS One. 2012 ; 7 (5). e37589
22. Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, Jordan KA. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci. 2004 ; 7 (7). 736-44
23. Kerlero de, Rosbo N, Mendel I, Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol. 1995 ; 25 (4). 985-93
24. Kim JE, Liu BP, Park JH, Strittmatter SM. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron. 2004 ; 44 (3). 439-51
25. Koutsoudaki PN, Hildebrandt H, Gudi V, Skripuletz T, Skuljec J, Stangel M. Remyelination after cuprizone induced demyelination is accelerated in mice deficient in the polysialic acid synthesizing enzyme St8siaIV. Neuroscience. 2010 ; 171 (1). 235-44
26. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012 ; 8 (11). 647-56
27. Lau LW, Keough MB, Haylock-Jacobs S, Cua R, Doring A, Sloka S. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol. 2012 ; 72 (3). 419-32
28. Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y. Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J Neurosci. 2008 ; 28 (11). 2753-65
29. Lee JK, Chow R, Xie F, Chow SY, Tolentino KE, Zheng B. Combined genetic attenuation of myelin and semaphorin-mediated growth inhibition is insufficient to promote serotonergic axon regeneration. J Neurosci. 2010 ; 30 (32). 10899-904
30. Lindsey JW, Crawford MP, Hatfield LM. Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis. Neurology. 2008 ; 71 (1). 35-7
31. Matsushita H, Endo S, Kobayashi E, Sakamoto Y, Kobayashi K, Kitaguchi K. Differential but competitive binding of Nogo protein and class I major histocompatibility complex (MHCI) to the PIR-B ectodomain provides an inhibition of cells. J Biol Chem. 2011 ; 286 (29). 25739-47
32. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007 ; 13 (10). 1228-33
33. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005 ; 8 (6). 745-51
34. Nakaya N, Sultana A, Lee HS, Tomarev SI. Olfactomedin 1 interacts with the Nogo A receptor complex to regulate axon growth. J Biol Chem. 2012 ; 287: 37171-84
35. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011 ; 17 (4). 495-9
36. Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res. 2012 ; 349 (1). 97-104
37. Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 ; 135 (Pt 6). 1794-818
38. Petrinovic MM, Hourez R, Aloy EM, Dewarrat G, Gall D, Weinmann O. Neuronal Nogo-A negatively regulates dendritic morphology and synaptic transmission in the cerebellum. Proc Natl Acad Sci U S A. 2012 ; 110 (3). 1083-8
39. Pool M, Niino M, Rambaldi I, Robson K, Bar-Or A, Fournier AE. Myelin regulates immune cell adhesion and motility. Exp Neurol. 2009 ; 217 (2). 371-7
40. Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis. 2004 ; 15 (3). 415-36
41. Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J. Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. J Neurosci. 2009 ; 29 (18). 5768-83
42. Rolando C, Parolisi R, Boda E, Schwab ME, Rossi F, Buffo A. Distinct roles of Nogo-a and Nogo receptor 1 in the homeostatic regulation of adult neural stem cell function and neuroblast migration. J Neurosci. 2012 ; 32 (49). 17788-99
43. Ruckh JM, Zhao JW, Shadrach JL, van Wijngaarden P, Rao TN, Wagers AJ. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell. 2012 ; 10 (1). 96-103
44. Satoh J, Onoue H, Arima K, Yamamura T. Nogo-A and Nogo receptor expression in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol. 2005 ; 64 (2). 129-38
45. Schwab ME. Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci. 2010 ; 11 (12). 799-811
46. Siebert JR, Stelzner DJ, Osterhout DJ. Chondroitinase treatment following spinal contusion injury increases migration of oligodendrocyte progenitor cells. Exp Neurol. 2011 ; 231 (1). 19-29
47. Siffrin V, Radbruch H, Glumm R, Niesner R, Paterka M, Herz J. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity. 2010 ; 33 (3). 424-36
48. Steinbach K, McDonald CL, Reindl M, Schweigreiter R, Bandtlow C, Martin R. Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis. PloS One. 2011 ; 6 (11). e26341
49. Teng FY, Tang BL. Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?. J Neurochem. 2005 ; 94 (4). 865-74
50. Theotokis P, Lourbopoulos A, Touloumi O, Lagoudaki R, Kofidou E, Nousiopoulou E. Time course and spatial profile of Nogo-A expression in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuropathol Exp Neurol. 2012 ; 71 (10). 907-20
51. Thomas R, Favell K, Morante-Redolat J, Pool M, Kent C, Wright M. LGI1 is a Nogo receptor 1 ligand that antagonizes myelin-based growth inhibition. J Neurosci. 2010 ; 30 (19). 6607-12
52. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci. 2008 ; 31: 247-69
53. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338 (5). 278-85
54. Wang X, Hasan O, Arzeno A, Benowitz LI, Cafferty WB, Strittmatter SM. Axonal regeneration induced by blockade of glial inhibitors coupled with activation of intrinsic neuronal growth pathways. Exp Neurol. 2012 ; 237 (1). 55-69
55. Wills ZP, Mandel-Brehm C, Mardinly AR, McCord AE, Giger RJ, Greenberg ME. The Nogo receptor family restricts synapse number in the developing hippocampus. Neuron. 2012 ; 73 (3). 466-81
56. Yan J, Zhou X, Guo JJ, Mao L, Wang YJ, Sun J. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J Neurochem. 2012 ; 120 (5). 721-31
57. Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol. 2010 ; 67 (4). 498-507
58. Zhang L, Zheng S, Wu H, Wu Y, Liu S, Fan M. Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J Neurosci. 2009 ; 29 (19). 6348-52
59. Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC. Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci U S A. 2005 ; 102 (4). 1205-10
60. Zorner B, Schwab ME. Anti-Nogo on the go: from animal models to a clinical trial. Ann N Y Acad Sci. 2010 1198 ;: E22 - E34